NHS England commissioning statement: Arrangements for access to cystic fibrosis transmembrane conductance regulator (CFTR) modulators for licensed and off-label use in patients with cystic fibrosis

Document first published:
Page updated:
Topic:
Publication type:

NHS England has confirmed that vanzacaftor–tezacaftor–deutivacaftor will be made available as a treatment option for people with cystic fibrosis (CF) who have 1 of an expanded range of CF transmembrane conductance regulator mutations within the criteria set out in this commissioning statement.

Link

Commissioning statement: NHS England commissioning statement: Arrangements for access to cystic fibrosis transmembrane conductance regulator (CFTR) modulators for licensed and off-label use in patients with cystic fibrosis

Commissioning statement: NHS England commissioning statement: Arrangements for access to cystic fibrosis transmembrane conductance regulator (CFTR) modulators for licensed and off-label use in patients with cystic fibrosis

NHS England is not responsible for content on external websites.

Summary

Accessible version published 15 July 2025